 | • レポートコード：MRC2-11QY10845 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は狭心症治療薬のグローバル市場について調査・分析したレポートです。種類別（ベータ遮断薬、カルシウム拮抗薬、抗凝固薬、抗血小板薬、その他）市場規模、用途別（病院、クリニック、ASC）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別狭心症治療薬の競争状況、市場シェア ・世界の狭心症治療薬市場：種類別市場規模 2015年-2020年（ベータ遮断薬、カルシウム拮抗薬、抗凝固薬、抗血小板薬、その他） ・世界の狭心症治療薬市場：種類別市場規模予測 2021年-2026年（ベータ遮断薬、カルシウム拮抗薬、抗凝固薬、抗血小板薬、その他） ・世界の狭心症治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、ASC） ・世界の狭心症治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、ASC） ・北米の狭心症治療薬市場分析：米国、カナダ ・ヨーロッパの狭心症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの狭心症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の狭心症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの狭心症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Bayer、AstraZeneca、Gilead、Novartis、GlaxoSmithKline、Merck、Mylan、Teva Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as – stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work.
Chronic stable angina pectoris has a prevalence of 2.0 – 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris.
Market Analysis and Insights: Global Angina Pectoris Drugs Market
The global Angina Pectoris Drugs market size is projected to reach US$ 9121.9 million by 2026, from US$ 8616.3 million in 2020, at a CAGR of 5.4%% during 2021-2026.
Global Angina Pectoris Drugs Scope and Market Size
Angina Pectoris Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Angina Pectoris Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Bayer
AstraZeneca
Gilead
Novartis
GlaxoSmithKline
Merck
Mylan
Teva Pharmaceutical
Market segment by Type, the product can be split into
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others
Market segment by Application, split into
Hospitals
Clinics
ASCs
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Angina Pectoris Drugs Revenue
1.4 Market by Type
1.4.1 Global Angina Pectoris Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Beta Blockers
1.4.3 Calcium Antagonists
1.4.4 Anticoagulants
1.4.5 Anti-Platelets
1.4.6 Others
1.5 Market by Application
1.5.1 Global Angina Pectoris Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 ASCs
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Angina Pectoris Drugs Market Perspective (2015-2026)
2.2 Global Angina Pectoris Drugs Growth Trends by Regions
2.2.1 Angina Pectoris Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Angina Pectoris Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Angina Pectoris Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Angina Pectoris Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Angina Pectoris Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Angina Pectoris Drugs Players by Market Size
3.1.1 Global Top Angina Pectoris Drugs Players by Revenue (2015-2020)
3.1.2 Global Angina Pectoris Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Angina Pectoris Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Angina Pectoris Drugs Market Concentration Ratio
3.2.1 Global Angina Pectoris Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Angina Pectoris Drugs Revenue in 2019
3.3 Angina Pectoris Drugs Key Players Head office and Area Served
3.4 Key Players Angina Pectoris Drugs Product Solution and Service
3.5 Date of Enter into Angina Pectoris Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Angina Pectoris Drugs Historic Market Size by Type (2015-2020)
4.2 Global Angina Pectoris Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Angina Pectoris Drugs Market Size by Application (2015-2020)
5.2 Global Angina Pectoris Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Angina Pectoris Drugs Market Size (2015-2020)
6.2 Angina Pectoris Drugs Key Players in North America (2019-2020)
6.3 North America Angina Pectoris Drugs Market Size by Type (2015-2020)
6.4 North America Angina Pectoris Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Angina Pectoris Drugs Market Size (2015-2020)
7.2 Angina Pectoris Drugs Key Players in Europe (2019-2020)
7.3 Europe Angina Pectoris Drugs Market Size by Type (2015-2020)
7.4 Europe Angina Pectoris Drugs Market Size by Application (2015-2020)
8 China
8.1 China Angina Pectoris Drugs Market Size (2015-2020)
8.2 Angina Pectoris Drugs Key Players in China (2019-2020)
8.3 China Angina Pectoris Drugs Market Size by Type (2015-2020)
8.4 China Angina Pectoris Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Angina Pectoris Drugs Market Size (2015-2020)
9.2 Angina Pectoris Drugs Key Players in Japan (2019-2020)
9.3 Japan Angina Pectoris Drugs Market Size by Type (2015-2020)
9.4 Japan Angina Pectoris Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Angina Pectoris Drugs Market Size (2015-2020)
10.2 Angina Pectoris Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Angina Pectoris Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Angina Pectoris Drugs Market Size by Application (2015-2020)
11 India
11.1 India Angina Pectoris Drugs Market Size (2015-2020)
11.2 Angina Pectoris Drugs Key Players in India (2019-2020)
11.3 India Angina Pectoris Drugs Market Size by Type (2015-2020)
11.4 India Angina Pectoris Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Angina Pectoris Drugs Market Size (2015-2020)
12.2 Angina Pectoris Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Angina Pectoris Drugs Market Size by Type (2015-2020)
12.4 Central & South America Angina Pectoris Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Angina Pectoris Drugs Introduction
13.1.4 Pfizer Revenue in Angina Pectoris Drugs Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Bayer
13.2.1 Bayer Company Details
13.2.2 Bayer Business Overview
13.2.3 Bayer Angina Pectoris Drugs Introduction
13.2.4 Bayer Revenue in Angina Pectoris Drugs Business (2015-2020)
13.2.5 Bayer Recent Development
13.3 AstraZeneca
13.3.1 AstraZeneca Company Details
13.3.2 AstraZeneca Business Overview
13.3.3 AstraZeneca Angina Pectoris Drugs Introduction
13.3.4 AstraZeneca Revenue in Angina Pectoris Drugs Business (2015-2020)
13.3.5 AstraZeneca Recent Development
13.4 Gilead
13.4.1 Gilead Company Details
13.4.2 Gilead Business Overview
13.4.3 Gilead Angina Pectoris Drugs Introduction
13.4.4 Gilead Revenue in Angina Pectoris Drugs Business (2015-2020)
13.4.5 Gilead Recent Development
13.5 Novartis
13.5.1 Novartis Company Details
13.5.2 Novartis Business Overview
13.5.3 Novartis Angina Pectoris Drugs Introduction
13.5.4 Novartis Revenue in Angina Pectoris Drugs Business (2015-2020)
13.5.5 Novartis Recent Development
13.6 GlaxoSmithKline
13.6.1 GlaxoSmithKline Company Details
13.6.2 GlaxoSmithKline Business Overview
13.6.3 GlaxoSmithKline Angina Pectoris Drugs Introduction
13.6.4 GlaxoSmithKline Revenue in Angina Pectoris Drugs Business (2015-2020)
13.6.5 GlaxoSmithKline Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview
13.7.3 Merck Angina Pectoris Drugs Introduction
13.7.4 Merck Revenue in Angina Pectoris Drugs Business (2015-2020)
13.7.5 Merck Recent Development
13.8 Mylan
13.8.1 Mylan Company Details
13.8.2 Mylan Business Overview
13.8.3 Mylan Angina Pectoris Drugs Introduction
13.8.4 Mylan Revenue in Angina Pectoris Drugs Business (2015-2020)
13.8.5 Mylan Recent Development
13.9 Teva Pharmaceutical
13.9.1 Teva Pharmaceutical Company Details
13.9.2 Teva Pharmaceutical Business Overview
13.9.3 Teva Pharmaceutical Angina Pectoris Drugs Introduction
13.9.4 Teva Pharmaceutical Revenue in Angina Pectoris Drugs Business (2015-2020)
13.9.5 Teva Pharmaceutical Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Angina Pectoris Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Angina Pectoris Drugs Revenue
Table 3. Ranking of Global Top Angina Pectoris Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Angina Pectoris Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Beta Blockers
Table 6. Key Players of Calcium Antagonists
Table 7. Key Players of Anticoagulants
Table 8. Key Players of Anti-Platelets
Table 9. Key Players of Others
Table 10. Global Angina Pectoris Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Angina Pectoris Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Angina Pectoris Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Angina Pectoris Drugs Market Share by Regions (2015-2020)
Table 14. Global Angina Pectoris Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Angina Pectoris Drugs Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Angina Pectoris Drugs Market Growth Strategy
Table 20. Main Points Interviewed from Key Angina Pectoris Drugs Players
Table 21. Global Angina Pectoris Drugs Revenue by Players (2015-2020) (Million US$)
Table 22. Global Angina Pectoris Drugs Market Share by Players (2015-2020)
Table 23. Global Top Angina Pectoris Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Angina Pectoris Drugs as of 2019)
Table 24. Global Angina Pectoris Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Angina Pectoris Drugs Product Solution and Service
Table 27. Date of Enter into Angina Pectoris Drugs Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Angina Pectoris Drugs Market Size by Type (2015-2020) (Million US$)
Table 30. Global Angina Pectoris Drugs Market Size Share by Type (2015-2020)
Table 31. Global Angina Pectoris Drugs Revenue Market Share by Type (2021-2026)
Table 32. Global Angina Pectoris Drugs Market Size Share by Application (2015-2020)
Table 33. Global Angina Pectoris Drugs Market Size by Application (2015-2020) (Million US$)
Table 34. Global Angina Pectoris Drugs Market Size Share by Application (2021-2026)
Table 35. North America Key Players Angina Pectoris Drugs Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Angina Pectoris Drugs Market Share (2019-2020)
Table 37. North America Angina Pectoris Drugs Market Size by Type (2015-2020) (Million US$)
Table 38. North America Angina Pectoris Drugs Market Share by Type (2015-2020)
Table 39. North America Angina Pectoris Drugs Market Size by Application (2015-2020) (Million US$)
Table 40. North America Angina Pectoris Drugs Market Share by Application (2015-2020)
Table 41. Europe Key Players Angina Pectoris Drugs Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Angina Pectoris Drugs Market Share (2019-2020)
Table 43. Europe Angina Pectoris Drugs Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Angina Pectoris Drugs Market Share by Type (2015-2020)
Table 45. Europe Angina Pectoris Drugs Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Angina Pectoris Drugs Market Share by Application (2015-2020)
Table 47. China Key Players Angina Pectoris Drugs Revenue (2019-2020) (Million US$)
Table 48. China Key Players Angina Pectoris Drugs Market Share (2019-2020)
Table 49. China Angina Pectoris Drugs Market Size by Type (2015-2020) (Million US$)
Table 50. China Angina Pectoris Drugs Market Share by Type (2015-2020)
Table 51. China Angina Pectoris Drugs Market Size by Application (2015-2020) (Million US$)
Table 52. China Angina Pectoris Drugs Market Share by Application (2015-2020)
Table 53. Japan Key Players Angina Pectoris Drugs Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Angina Pectoris Drugs Market Share (2019-2020)
Table 55. Japan Angina Pectoris Drugs Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Angina Pectoris Drugs Market Share by Type (2015-2020)
Table 57. Japan Angina Pectoris Drugs Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Angina Pectoris Drugs Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Angina Pectoris Drugs Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Angina Pectoris Drugs Market Share (2019-2020)
Table 61. Southeast Asia Angina Pectoris Drugs Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Angina Pectoris Drugs Market Share by Type (2015-2020)
Table 63. Southeast Asia Angina Pectoris Drugs Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Angina Pectoris Drugs Market Share by Application (2015-2020)
Table 65. India Key Players Angina Pectoris Drugs Revenue (2019-2020) (Million US$)
Table 66. India Key Players Angina Pectoris Drugs Market Share (2019-2020)
Table 67. India Angina Pectoris Drugs Market Size by Type (2015-2020) (Million US$)
Table 68. India Angina Pectoris Drugs Market Share by Type (2015-2020)
Table 69. India Angina Pectoris Drugs Market Size by Application (2015-2020) (Million US$)
Table 70. India Angina Pectoris Drugs Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Angina Pectoris Drugs Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Angina Pectoris Drugs Market Share (2019-2020)
Table 73. Central & South America Angina Pectoris Drugs Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Angina Pectoris Drugs Market Share by Type (2015-2020)
Table 75. Central & South America Angina Pectoris Drugs Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Angina Pectoris Drugs Market Share by Application (2015-2020)
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Product
Table 80. Pfizer Revenue in Angina Pectoris Drugs Business (2015-2020) (Million US$)
Table 81. Pfizer Recent Development
Table 82. Bayer Company Details
Table 83. Bayer Business Overview
Table 84. Bayer Product
Table 85. Bayer Revenue in Angina Pectoris Drugs Business (2015-2020) (Million US$)
Table 86. Bayer Recent Development
Table 87. AstraZeneca Company Details
Table 88. AstraZeneca Business Overview
Table 89. AstraZeneca Product
Table 90. AstraZeneca Revenue in Angina Pectoris Drugs Business (2015-2020) (Million US$)
Table 91. AstraZeneca Recent Development
Table 92. Gilead Company Details
Table 93. Gilead Business Overview
Table 94. Gilead Product
Table 95. Gilead Revenue in Angina Pectoris Drugs Business (2015-2020) (Million US$)
Table 96. Gilead Recent Development
Table 97. Novartis Company Details
Table 98. Novartis Business Overview
Table 99. Novartis Product
Table 100. Novartis Revenue in Angina Pectoris Drugs Business (2015-2020) (Million US$)
Table 101. Novartis Recent Development
Table 102. GlaxoSmithKline Company Details
Table 103. GlaxoSmithKline Business Overview
Table 104. GlaxoSmithKline Product
Table 105. GlaxoSmithKline Revenue in Angina Pectoris Drugs Business (2015-2020) (Million US$)
Table 106. GlaxoSmithKline Recent Development
Table 107. Merck Company Details
Table 108. Merck Business Overview
Table 109. Merck Product
Table 110. Merck Revenue in Angina Pectoris Drugs Business (2015-2020) (Million US$)
Table 111. Merck Recent Development
Table 112. Mylan Business Overview
Table 113. Mylan Product
Table 114. Mylan Company Details
Table 115. Mylan Revenue in Angina Pectoris Drugs Business (2015-2020) (Million US$)
Table 116. Mylan Recent Development
Table 117. Teva Pharmaceutical Company Details
Table 118. Teva Pharmaceutical Business Overview
Table 119. Teva Pharmaceutical Product
Table 120. Teva Pharmaceutical Revenue in Angina Pectoris Drugs Business (2015-2020) (Million US$)
Table 121. Teva Pharmaceutical Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Angina Pectoris Drugs Market Share by Type: 2020 VS 2026
Figure 2. Beta Blockers Features
Figure 3. Calcium Antagonists Features
Figure 4. Anticoagulants Features
Figure 5. Anti-Platelets Features
Figure 6. Others Features
Figure 7. Global Angina Pectoris Drugs Market Share by Application: 2020 VS 2026
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. ASCs Case Studies
Figure 11. Angina Pectoris Drugs Report Years Considered
Figure 12. Global Angina Pectoris Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Angina Pectoris Drugs Market Share by Regions: 2020 VS 2026
Figure 14. Global Angina Pectoris Drugs Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Angina Pectoris Drugs Market Share by Players in 2019
Figure 17. Global Top Angina Pectoris Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Angina Pectoris Drugs as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Angina Pectoris Drugs Revenue in 2019
Figure 19. North America Angina Pectoris Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Angina Pectoris Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Angina Pectoris Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Angina Pectoris Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Angina Pectoris Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Angina Pectoris Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Angina Pectoris Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
狭心症治療の世界市場（～2026年） Market Analysis and Insights: Global Angina Pectoris Treatment Market The global Angina Pectoris Treatment market size is projected to reach US$ 7908.5 million by 2026, from US$ 7756.3 million in 2020, at a CAGR of 1.8%% during 2021-2026. Global Angina Pectoris Treatment Scope and Market Size Angina…- 虚血性心疾患（IHD）薬の世界市場（～2026年） Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may tr…
- 抗高血圧薬の世界市場（～2026年） Market Analysis and Insights: Global Anti-Hypertensive Drugs Market The global Anti-Hypertensive Drugs market size is projected to reach US$ 40970 million by 2026, from US$ 40270 million in 2020, at a CAGR of 1.6%% during 2021-2026. Global Anti-Hypertensive Drugs Scope and Market Size Anti-Hypertens…
- バーター症候群治療薬の世界市場（～2026年） Bartter syndrome is a rare genetic disorder that causes specific defects in kidney function. Market Analysis and Insights: Global Bartter Syndrome Drugs Market The global Bartter Syndrome Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% d…
- 抗糖尿病治療薬の世界市場（～2026年） The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for…